Published in J Immunol on November 01, 1978
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest (1983) 2.32
Enhancement of human natural cell-mediated cytotoxicity by interferon. Br J Cancer (1980) 1.11
Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infect Immun (1983) 1.04
Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med (1982) 0.84
Effects of interferons and interleukin 2 on natural killing of cytomegalovirus-infected fibroblasts. Clin Exp Immunol (1987) 0.77
Effects of interferons on human B-cell differentiation in vitro. Korean J Intern Med (1987) 0.75
Biosynthetic human interferon treatment of herpetic keratitis. Trans Am Ophthalmol Soc (1983) 0.75
Role of IL-2 and interferon in the generation of natural cytotoxic activity in influenza virus-stimulated PBL cultures: analysis with the use of prednisolone. Clin Exp Immunol (1988) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res (1980) 2.97
Functional analysis of human T cell subsets defined by monoclonal antibodies. I. Collaborative T-T interactions in the immunoregulation of B cell differentiation. J Immunol (1980) 2.93
Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science (1992) 2.83
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens. J Immunol (1984) 2.14
Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Monoclonal antibodies which distinguish between human NK cells and cytotoxic T lymphocytes. Nature (1980) 1.99
Phenotypes of human natural killer cell populations detected with monoclonal antibodies. J Immunol (1981) 1.99
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Streptovaricins inhibit RNA dependent DNA polymerase present in an oncogenic RNA virus. Nature (1971) 1.85
Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol (1999) 1.81
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol (1989) 1.75
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Molecular basis of the action of interferon. J Mol Biol (1968) 1.70
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A (1986) 1.69
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J Immunol (1986) 1.65
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Generation of cytotoxic lymphocytes in vitro against autologous human leukaemia cells. Nature (1976) 1.64
Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol (1987) 1.63
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Rapid improvement of acute pulmonary edema with sublingual captopril. Acad Emerg Med (1996) 1.55
T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature (1986) 1.55
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47
Continuous culture of T cells cytotoxic for autologous human leukaemia cells. Nature (1979) 1.46
In vitro assessment of cellular immunity to vaccinia virus: contribution of lymphocytes and macrophages. Infect Immun (1970) 1.46
Ribosomes: effect of interferon on their interaction with rapidly labeled cellular and viral RNA's. Science (1967) 1.44
The recognition of viral RNA by mammalian ribosomes. An effect of interferon. Biochim Biophys Acta (1968) 1.44
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol (1995) 1.41
Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells. Nature (1978) 1.41
Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro (1982) 1.39
Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. I. Development of cellular immunity to simian virus 40 tumor-specific transplantation antigens during tumorigenesis by transplanted cells. J Natl Cancer Inst (1973) 1.38
Functional analysis of human T cell subsets defined by monoclonal antibodies. III. Regulation of helper factor production by T cell subsets. J Immunol (1981) 1.38
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38
Glycosylation of interferons. Effects of tunicamycin on human immune interferon. J Biol Chem (1978) 1.35
The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34
Structural requirements of the rI n -rC n complex for induction of human interferon. J Mol Biol (1972) 1.33
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus. J Virol (1986) 1.33
Molecular structure of human fibroblast and leukocyte interferons: probe by lectin and hydrophobic chromatography. J Virol (1975) 1.32
Binding of human interferons to immobolized Cibacron Blue F3GA: The nature of molecular interaction. Biochemistry (1976) 1.32
Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection. J Natl Cancer Inst (1973) 1.31
Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology (1990) 1.31
Friend leukemia: rapid development of erythropoietin-independent hematopoietic precursors. J Natl Cancer Inst (1975) 1.30
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol (2000) 1.28
Histamine inhibition of neutrophil lysosomal enzyme release: an H2 histamine receptor response. Science (1976) 1.27
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25
Binding of human fibroblast interferon to concanavalin A-agarose. Involvement of carbohydrate recognition and hydrophobic interaction. Biochemistry (1976) 1.25
T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. J Virol (1987) 1.24
Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc Natl Acad Sci U S A (1989) 1.21
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
Lysis of leukemia cells by spleen cells of normal mice. Proc Natl Acad Sci U S A (1975) 1.20
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
Selective binding of human interferon to albumin immoblized on agarose. J Biol Chem (1974) 1.17
Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer (1981) 1.16
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis (1994) 1.14
Interaction of human interferons with immobilized hydrophobic amino acids and dipeptides. J Biol Chem (1976) 1.14
An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14
Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13
Hydrophobic interaction of human interferon with concanavalin A-agarose. J Biol Chem (1974) 1.13
Summary of workshop findings for leukocyte antigens of cattle. Vet Immunol Immunopathol (1991) 1.12
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant (2000) 1.09
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet (1987) 1.09
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09
Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis (1996) 1.09
Viral infection and host defense. Science (1974) 1.08
Depletion of human NK cells with monoclonal antibodies allows the generation of cytotoxic T lymphocytes without NK-like cells in mixed cultures. J Immunol (1983) 1.08
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res (1997) 1.06
Interferon: evidence for subunit structure. Proc Natl Acad Sci U S A (1970) 1.06
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol (2002) 1.05
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
A sensitive micromethod for generating and assaying allogeneically induced cytotoxic human lymphocytes. Transplantation (1976) 1.04
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03